.Attribute Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint asks for inclusion of patients along with MASLD as well as size of liver outcomes in cardio-- kidney-- metabolic trials, when information propose mechanistically probable perks as well as clinical security-- and summarizes factors for test concept as well as regulatory approval.